Relypsa (RLYP) Misses Q4 EPS by 5c; Provides 'Encouraging' Initial Veltassa Script Data

Relypsa (RLYP) PT Lowered to $36 at Stifel; Upbeat on Initial Launch Metrics, sNDA Prospects

Stifel analyst Stephen Willey trimmed his price target on Relypsa, Inc. (NASDAQ: RLYP) to $36.00 (from $40.00) following fourth quarter results and preliminary Veltassa launch metrics.

Willey called the launch metrics "highly encouraging" and was positive on the sNDA prospects.

"This includes the >1,200 unique outpatient prescriptions written/received by the companys... More

BTIG Affirms Relypsa (RLYP) at 'Buy'; Sees Veltassa Ramp in H216 as Formulary Coverage Obtained

BTIG reaffirms its Buy rating and $45 price target on Relypsa (Nasdaq: RLYP) following Q4 results issued Wednesday night. Largely, the firm is looking for Valtassa sales to ramp in the second-half of the year as formulary coverage begins to kick in.

Analyst... More

Relypsa (RLYP) PT Trimmed to $29 at BofA/Merrill Lynch Post Q4; Maintains Bullish View

BofA/Merrill Lynch analyst Catherine Hu trimmed her price target on Relypsa, Inc. (NASDAQ: RLYP) to $29.00 (from $32.00) following Q4 results and initial Veltassa numbers but maintained a Buy rating.

On the Veltassa launch, Hu said while it's too early to tell the trajectory encouraging.

The analyst notes that since the beginning of the launch in late Dec, 1,229 new outpatient prescriptions have been written as Feb 12. In Jan, 409 patients received a free starter... More

Relypsa (RLYP) PT Lowered to $53 at Wedbush; Initial Veltassa Prescriptions Below Our Estimates But Accelerating

Wedbush analyst Liana Moussatos cut her price target on Relypsa, Inc. (Nasdaq: RLYP) from $86 down to $53 following earnings and initial Veltassa prescription data, but maintained an Outperform rating.

"Veltassa's launch was slower than we expected but accelerating," Moussatos said. "Through February 12th, 815 patients... More